

List of Drugs for an Urgent Public Health Need

Brand name	Medicinal ingredient(s)	Dosage form	Strength	Route of administration	Foreign identifying code or number	For Information Purposes				
						Foreign regulatory authority/ Foreign country	Canadian jurisdiction notifying for the drug	Urgent public health need	Applicable Foreign Authorised Indication (Intended use or purpose of the drug)	Date of notification by a public health official
Priftin	rifapentine	Tablet	150 mg	Oral	0088-2100-24	FDA/USA	First Nations and Inuit Health Branch	Tuberculosis crisis	For the treatment of latent tuberculosis infection (LTBI) caused by <i>Mycobacterium tuberculosis</i> in combination with isoniazid in patients at high risk of progression to TB disease.	May 23, 2019
Priftin	rifapentine	Tablet	150 mg	Oral	0088-2100-24	FDA/USA	Newfoundland/Labrador	Tuberculosis crisis	For the treatment of latent tuberculosis infection (LTBI) caused by <i>Mycobacterium tuberculosis</i> in combination with isoniazid in patients at high risk of progression to TB disease.	April 29, 2019
Priftin	rifapentine	Tablet	150 mg	Oral	0088-2100-24	FDA/USA	Manitoba	Tuberculosis crisis	For the treatment of latent tuberculosis infection (LTBI) caused by <i>Mycobacterium tuberculosis</i> in combination with isoniazid in patients at high risk of progression to TB disease.	September 6, 2018
Priftin	rifapentine	Tablet	150 mg	Oral	0088-2102-24	FDA/USA	Public Health Agency of Canada – for use in Correctional Service Canada Facilities	Tuberculosis crisis	For the treatment of latent tuberculosis infection (LTBI) caused by <i>Mycobacterium tuberculosis</i> in combination with isoniazid in patients at high risk of progression to TB disease.	December 12, 2018

Brand name	Medicinal ingredient(s)	Dosage form	Strength	Route of administration	Foreign identifying code or number	For Information Purposes				
						Foreign regulatory authority/ Foreign country	Canadian jurisdiction notifying for the drug	Urgent public health need	Applicable Foreign Authorised Indication (Intended use or purpose of the drug)	Date of notification by a public health official
Suboxone	buprenorphine hydrochloride; naloxone hydrochloride	Film	2 mg/ 0.5 mg; 8 mg/2 mg; 12 mg/3 mg	Buccal, Sublingual	12496-1202-3 12496-1208-3 12496-1212-3	FDA/USA	Public Health Agency of Canada – for use in Correctional Service Canada Facilities	Opioid crisis	For the treatment of opioid dependence and as part of a complete treatment plan to include counseling and psychosocial support.	December 12, 2018
Sublocade	buprenorphine	Injectable	100mg/0.5ml 300mg/1.5ml	Subcutaneous	12496-0100-1 12496-0300-1	FDA/USA	Public Health Agency of Canada – for use in Correctional Service Canada Facilities	Opioid crisis	For the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a transmucosal buprenorphine containing-product, followed by dose adjustment for a minimum of 7 days	December 12, 2018
Priftin	rifapentine	Tablet	150 mg	Oral	0088-2100-24	FDA/USA	Yukon	Tuberculosis crisis	For the treatment of latent tuberculosis infection (LTBI) caused by <i>Mycobacterium tuberculosis</i> in combination with isoniazid in patients at high risk of progression to TB disease.	November 2, 2018

Brand name	Medicinal ingredient(s)	Dosage form	Strength	Route of administration	Foreign identifying code or number	For Information Purposes				
						Foreign regulatory authority/ Foreign country	Canadian jurisdiction notifying for the drug	Urgent public health need	Applicable Foreign Authorised Indication (Intended use or purpose of the drug)	Date of notification by a public health official
Priftin	rifapentine	Tablet	150 mg	Oral	0088-2100-24	FDA/USA	Alberta	Tuberculosis crisis	For the treatment of latent tuberculosis infection (LTBI) caused by <i>Mycobacterium tuberculosis</i> in combination with isoniazid in patients at high risk of progression to TB disease.	November 20, 2018
Priftin	rifapentine	Tablet	150 mg	Oral	0088-2102-24	FDA/USA	Northwest Territories	Tuberculosis crisis	For the treatment of latent tuberculosis infection (LTBI) caused by <i>Mycobacterium tuberculosis</i> in combination with isoniazid in patients at high risk of progression to TB disease.	January 7, 2019
Priftin	rifapentine	Tablet	150 mg	Oral	0088-2100-24	FDA/USA	Ontario	Tuberculosis crisis	For the treatment of latent tuberculosis infection (LTBI) caused by <i>Mycobacterium tuberculosis</i> in combination with isoniazid in patients at high risk of progression to TB disease.	March 21, 2019
Priftin	rifapentine	Tablet	150 mg	Oral	0088-2100-24	FDA/USA	Saskatchewan	Tuberculosis crisis	For the treatment of latent tuberculosis infection (LTBI) caused by <i>Mycobacterium tuberculosis</i> in combination with isoniazid in patients at high risk of progression to TB disease.	November 21, 2018

Brand name	Medicinal ingredient(s)	Dosage form	Strength	Route of administration	Foreign identifying code or number	For Information Purposes				
						Foreign regulatory authority/ Foreign country	Canadian jurisdiction notifying for the drug	Urgent public health need	Applicable Foreign Authorised Indication (Intended use or purpose of the drug)	Date of notification by a public health official
Diaphin i.v.	diamorphine	Injectable	10 g/vial	Intravenous	55561	Swissmedic/ Switzerland	Public Health Agency of Canada	Opioid crisis	Substitution therapy in case of severe heroin dependence as part of a treatment program with prescription heroin.	April 25, 2019
Priftin	rifapentine	Tablet	150 mg	Oral	0088-2102-24	FDA/USA	Public Health Agency of Canada	Tuberculosis crisis	For the treatment of latent tuberculosis infection (LTBI) caused by <i>Mycobacterium tuberculosis</i> in combination with isoniazid in patients at high risk of progression to TB disease.	May 31, 2019